| Biocon markets Advacan, renal transplantation immunosuppressant, 45% lower ... - pharmabiz.com |
|
|
pharmabiz.com Biocon's renal transplantation immunosuppressant drug, everolimus with brand name, Advacan is priced 45 per cent lower than the innovator brand, 'Certican' of Novartis. The drug now is being prescribed to 180 patients since its launch 210 days ago, |